Drug intelligence / Profile preview

JTT-252

Development stage: Discontinued
Lead developer: Shionogi
Modality: Small Molecules
Administration: Oral

Overview

JTT-252 is an experimental pharmaceutical compound developed for the treatment of type 2 diabetes. It is a small molecule drug candidate, but detailed information about its mechanism of action has not been published in the available sources. The drug was under clinical investigation to evaluate its efficacy, safety, tolerability, and pharmacokinetics in patients with type 2 diabetes. Clinical development was led by Akros Pharma Inc., a company specializing in innovative therapeutic solutions and clinical research[2].

Targets

SLC5A1 (Sodium Glucose Cotransporter 1)

Beyond the preview

Go deeper on JTT-252.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JTT-252.

Explore the full profile